Share Twitter LinkedIn Facebook Email Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for breast cancer.
Enhertu DESTINY-Breast06 Phase III Study the Impact on HR-Positive, HER2-Low Metastatic Breast Cancer Revealed Breast 4 Mins Read
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read